The global pemetrexed market size was valued at USD 2.38 billion in 2025 and is projected to grow from USD 2.42 billion in 2026 to USD 2.75 billion by 2034, registering a CAGR of 1.6% during the forecast period from 2026 to 2034. North America dominated the pemetrexed market with a market share of 41.59% in 2025.
Pemetrexed is an antifolate chemotherapy drug used to treat certain types of cancer by interfering with folate-dependent processes required for cancer-cell growth and replication. It is primarily used in the treatment of non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, either alone or in combination with other anticancer therapies such as platinum-based chemotherapy and immunotherapy. Pemetrexed is generally administered as an intravenous injection and is available in various formulations and strengths.
Download a Free Sample To learn more about this report,
Immunotherapy Combinations Expand Pemetrexed-Based Lung Cancer Regimens
Treatment strategies for metastatic non-squamous non-small cell lung cancer are increasingly combining pemetrexed with immune checkpoint inhibitors and platinum chemotherapy to address multiple disease pathways within the same regimen. The 2026 ASCO Living Guideline continues to identify pembrolizumab plus carboplatin and pemetrexed as an option for patients with non-squamous NSCLC, while current U.S. labeling covers pemetrexed with pembrolizumab and platinum chemotherapy for initial treatment in eligible metastatic patients. These combination approaches are consequently strengthening the role of pemetrexed within modern treatment regimens and supporting the market growth of combination-based therapies.
Maintenance Therapy Sustains Pemetrexed Use in Non-Squamous Lung Cancer
Long-term disease management is supporting continued pemetrexed use after initial platinum-based chemotherapy when patients achieve disease control. Current U.S. prescribing information specifies pemetrexed as a single-agent maintenance treatment after four cycles of platinum-based first-line chemotherapy, with treatment continuing until disease progression or unacceptable toxicity. This treatment pathway is therefore sustaining pemetrexed utilization beyond initial chemotherapy while strengthening its market outlook in advanced non-squamous lung cancer.
Non-Squamous NSCLC Treatment and Mesothelioma Treatment Requirements Drive Market
The incidence and treatment volume of non-squamous non-small cell lung cancer create a substantial patient base for pemetrexed-based chemotherapy. Pemetrexed remains an established treatment option for non-squamous NSCLC, particularly adenocarcinoma, supporting recurring requirements across oncology treatment settings. The broad clinical use of pemetrexed in this patient population strengthens market demand and supports market growth. A larger pool of eligible patients also increases recurring requirements for pemetrexed across hospital oncology departments and cancer treatment centers.
Malignant pleural mesothelioma creates a distinct treatment population for pemetrexed, with pemetrexed in combination with cisplatin established as a systemic treatment option. The need for chemotherapy among eligible mesothelioma patients supports utilization beyond the larger lung-cancer treatment segment. This additional oncology application broadens the addressable market and supports market expansion for pemetrexed suppliers. Continued treatment requirements across specialized oncology centers create an additional source of product utilization within the broader market ecosystem.
Treatment-Related Toxicities and Generic Competition Restrains Market Expansion
Pemetrexed treatment can cause adverse effects such as myelosuppression, fatigue, nausea, and mucositis, which can complicate chemotherapy management. The risk of treatment-related toxicity can require dose adjustments, supportive care, or treatment interruptions in certain patients. These clinical management requirements can restrict treatment suitability and slow market growth among patients with limited tolerance for chemotherapy. Additional monitoring and supportive-care requirements can increase the overall burden of pemetrexed-based treatment for oncology providers.
The availability of generic pemetrexed products increases price competition across hospitals, oncology centers, and pharmaceutical procurement channels. Lower-priced alternatives can reduce revenue potential for branded products and place greater pressure on manufacturers to compete through pricing. Intensifying generic competition can compress product margins and limit market expansion opportunities for higher-priced formulations. Greater availability of alternative suppliers can also make product differentiation and premium pricing more difficult across the competitive landscape.
Ready-to-Use Formulations and Patient-Support Programs Expand Market Opportunities
Pharmaceutical manufacturers can develop ready-to-use pemetrexed formulations that simplify preparation and handling within oncology pharmacies. Hospital pharmacies and infusion centers can benefit from formulations that reduce preparation steps and improve workflow efficiency. Companies with injectable oncology portfolios can generate additional revenue through differentiated formulation formats and hospital-focused product offerings. Simplified administration formats can also strengthen product positioning among healthcare providers seeking greater pharmacy workflow efficiency.
Pharmaceutical companies and oncology service providers can develop adherence support, treatment education, financial assistance, and care-coordination programs around pemetrexed therapy. Such services can improve patient engagement while creating additional value around established pharmaceutical products. Manufacturers can strengthen commercial relationships with oncology centers through integrated support programs and service-based offerings. Specialized support services can create recurring partnership opportunities for providers that combine pharmaceutical products with oncology care solutions.
Biomarker-Based Treatment Selection and Chemotherapy Administration Requirements Hinders Market
Oncology treatment decisions can depend on histology, disease characteristics, molecular testing, and patient-specific clinical factors. Such variations can make treatment selection and therapy planning more complex across different patient groups and healthcare settings. Differences in diagnostic capabilities can also complicate consistent treatment pathways across the broader market ecosystem. Uneven access to specialized diagnostic facilities can create additional variation in treatment decision-making across healthcare systems.
Pemetrexed treatment requires coordinated activities across prescribing, preparation, infusion administration, laboratory monitoring, and follow-up care. These requirements can place additional coordination demands on oncology departments and infusion centers with different staffing and workflow capabilities. Operational differences across treatment facilities can make standardized pemetrexed administration more difficult and affect the efficiency of oncology care delivery. Variations in clinical staffing and infusion-center capacity can further complicate consistent treatment workflows across the market landscape.
The non-squamous NSCLC segment accounted for a share of 75% in 2025 and is expected to grow at a CAGR of 6.5% during the forecast period, owing to the established use of pemetrexed-based treatment regimens in the management of non-squamous non-small cell lung cancer. The malignant pleural mesothelioma segment also contributes to market growth through the use of pemetrexed in combination treatment approaches, supporting overall market demand.
Request Customizationto receive a tailored report.
The hospitals segment accounted for a share of 45% in 2025, supported by the high volume of cancer diagnosis and treatment procedures performed in hospital settings and the availability of specialized oncology care. The online pharmacies segment is expected to grow at a CAGR of 7.5% during the forecast period, driven by increasing digital access to medicines, convenience, home delivery, and expanding online pharmaceutical services. The oncology centers segment supports the market ecosystem through specialized cancer treatment and chemotherapy services, while the offline pharmacies segment contributes through conventional medicine distribution and prescription fulfillment.
Speak to an Analystto discuss market opportunities.
The North America Pemetrexed Market accounted for the largest regional share of 41.59% in 2025, supported by a well-established oncology infrastructure, advanced diagnostic capabilities, and broad access to chemotherapy and targeted cancer treatments.
The U.S. Healthy People 2030 program targets a reduction in the lung-cancer death rate to 25.1 deaths per 100,000 people and an increase in lung-cancer screening among eligible adults to 7.5%. Broader implementation of screening and earlier diagnosis can increase the number of patients entering structured treatment pathways, supporting demand for established NSCLC therapies such as pemetrexed. The U.S. also recorded an estimated 226,650 new lung-cancer cases in 2025, maintaining a substantial treatment pool.
Canada is advancing organized lung-cancer screening across the country as part of the Canadian Strategy for Cancer Control, with federal health plans for 2026–27 specifically calling for expanded access to screening and early detection. The strategy is intended to improve earlier identification of lung cancer and strengthen cancer-care pathways. Greater screening coverage can support treatment demand, including for chemotherapy regimens in eligible NSCLC patients.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific Pemetrexed Market is expected to grow at a 7.5% CAGR during the forecast period, showcasing the fastest-growing regional market. A large lung-cancer patient population, expanding oncology infrastructure, and improving access to modern cancer therapies are supporting market growth.
Japan's National Cancer Center East Hospital performed 459 surgeries for primary lung cancer during fiscal 2025, compared with 433 in the previous fiscal year. The continued volume of lung-cancer treatment at major specialist centers reflects sustained demand for comprehensive oncology care. Expansion of advanced diagnosis and treatment pathways can support the use of established NSCLC therapies, including pemetrexed.
China continues to record a substantial lung-cancer burden, with lung cancer identified as the country's most common cancer and more than 1 million new cases reported in the latest national monitoring data. In 2025, Chinese researchers also reported progress in first-line treatment approaches for advanced NSCLC, reflecting continued development of the country's oncology treatment landscape. A large patient pool and expanding treatment options support demand for established chemotherapy medicines such as pemetrexed.
India's Ministry of Health identifies lung cancer as a major and continuing health challenge, with NSCLC representing a major category requiring systemic treatment. The country's expanding oncology infrastructure and increasing focus on earlier diagnosis are expected to widen access to cancer treatment. This creates a supportive environment for established chemotherapy agents used in NSCLC management, including pemetrexed.
South Korea continues to strengthen advanced cancer treatment and precision-oncology capabilities through its broader healthcare and biotechnology ecosystem. Expansion of targeted and combination treatment approaches for lung cancer is increasing the need for differentiated treatment pathways across NSCLC patients. This supports the continued role of established therapies such as pemetrexed within eligible treatment regimens.
The Europe Pemetrexed Market accounted for a 28% market share in 2025, supported by established oncology networks, public healthcare systems, and strong access to cancer diagnosis and treatment.
The UK continues to strengthen cancer diagnosis and treatment through the NHS's long-term cancer strategy, with earlier diagnosis remaining a central priority. The government's 2025 health reporting also highlighted ongoing changes in lung-cancer incidence, with incidence declining among men but increasing among women in England. Continued focus on earlier detection and treatment capacity should sustain demand for systemic therapies used in NSCLC.
Germany's national cancer-care system continues to address the substantial burden of lung and bronchial cancer. Federal statistics reported 45,148 deaths from lung and bronchial cancer in 2024, representing 19.6% of cancer deaths, while lung and bronchial cancer also accounted for the largest share of inpatient cancer cases. The persistent treatment burden supports continued demand for established NSCLC therapies, including pemetrexed.
France's 2021–2030 national cancer strategy targets improvements in survival for cancers with poor prognoses, explicitly including lung cancer. The country is also pursuing a goal under France 2030 to produce 20 biomedicines for cancers and chronic diseases by 2030, strengthening domestic oncology research and biopharmaceutical capabilities. These initiatives should improve cancer-care capacity and support demand for established and newer therapies across the treatment pathway.
The Middle East Pemetrexed Market is expected to grow at a 6.8% CAGR during the forecast period, supported by increasing cancer-care investment, improved oncology infrastructure, and broader access to modern medicines.
The UAE's Ministry of Health and Prevention established a National Multidisciplinary Committee for Cancer Case Assessment in 2025, strengthening coordinated evaluation of cancer cases. The initiative supports more structured multidisciplinary oncology care and reflects continued development of the country's cancer-treatment infrastructure. Improved coordination and access to specialized cancer services can support demand for established therapies used in eligible NSCLC patients.
WHO reported in 2025 that the African Region recorded more than 900,000 new cancer cases and over 580,000 cancer deaths, highlighting the continuing need for stronger cancer diagnosis and treatment capacity. Lung cancer is among the important cancer types contributing to the regional burden. Expansion of oncology services and treatment access therefore provides a potential foundation for greater use of systemic therapies, including pemetrexed, across eligible NSCLC patients.
The pemetrexed market competitive landscape is moderately fragmented, with competition comprising originator pharmaceutical companies, generic oncology-drug manufacturers, specialty injectable-drug companies, and diversified pharmaceutical suppliers. Key players such as Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., Fresenius Kabi USA, and Teva Pharmaceuticals USA Inc. collectively are estimated to account for approximately 35% of the global pemetrexed market share, with competition extending across branded and generic injectable formulations. Eli Lilly markets Alimta (pemetrexed injection), while Eagle Pharmaceuticals, Fresenius Kabi, and other manufacturers supply generic pemetrexed products, contributing to a competitive market ecosystem.
Established players compete primarily on product quality, regulatory approvals, manufacturing capabilities, and oncology distribution networks. Emerging and regional players in the pemetrexed market ecosystem compete through cost-efficient generic formulations, reliable injectable supply, localized distribution, and expanded product availability, supporting market growth and market expansion across hospital pharmacies and oncology treatment settings.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Docetaxel Market Size, Share, Growth, Analysis, Report, 2034
Phenylketonuria Market Size, Share, Growth, Analysis, Report, 2034
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
Tulathromycin Market Size, Share, Growth, Analysis, Report, 2034
Renal Replacement Therapy Market Size, Share, Growth, 2034
Advanced Cancer Pain Management Market Size, Share, 2034
We are featured on:
sales@straitsresearch.com